XPO1 and non-small cell lung carcinoma: Thus, in this study, we explored the therapeutic efficiency of these novel drug-like CRM1 inhibitors (i.e., KPT-185 and KPT-276) in NSCLC cells in vitro and in vivo to hopefully provide novel insight into these drugs for future target therapy of NSCLC.